دورية أكاديمية
أعرض في EDS

Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants.

التفاصيل البيبلوغرافية
العنوان: Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants.
المؤلفون: Bricker KM; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Obregon-Perko V; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Williams B; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Oliver D; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Uddin F; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Neja M; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Hopkins L; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Dashti A; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Jean S; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Wood JS; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA., Ehnert S; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA., Liang S; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA., Vanderford T; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA., Tharp GK; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA., Bosinger SE; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA., Schauer AP; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA., Mavigner M; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA.; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA., Cottrell ML; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA., Margolis D; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.; Center for AIDS Research, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.; UNC HIV Cure Center, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.; Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA., Dunham RM; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.; UNC HIV Cure Center, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.; Qura Therapeutics, Chapel Hill, Research Triangle Park, North Carolina, USA.; HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, North Carolina, USA., Chahroudi A; Department of Pediatrics, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA.; Yerkes National Primate Research Center, Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA.; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta and Emory Universitygrid.471395.dgrid.189967.8grid.471395.dgrid.189967.8, Atlanta, Georgia, USA.
المصدر: Journal of virology [J Virol] 2022 Apr 13; Vol. 96 (7), pp. e0169921. Date of Electronic Publication: 2022 Mar 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-5514 (Electronic) Linking ISSN: 0022538X NLM ISO Abbreviation: J Virol Subsets: MEDLINE
أسماء مطبوعة: Publication: Washington Dc : American Society For Microbiology
Original Publication: Baltimore, American Society for Microbiology.
مواضيع طبية MeSH: HIV Infections*/drug therapy , HIV-1*/genetics , Simian Acquired Immunodeficiency Syndrome*/drug therapy , Simian Acquired Immunodeficiency Syndrome*/immunology , Simian Immunodeficiency Virus*, Alkynes/pharmacokinetics ; Alkynes/pharmacology ; Alkynes/therapeutic use ; Animals ; Anti-Retroviral Agents/pharmacokinetics ; Anti-Retroviral Agents/pharmacology ; Anti-Retroviral Agents/therapeutic use ; CD4-Positive T-Lymphocytes ; Humans ; Macaca mulatta ; Oligopeptides/pharmacokinetics ; Oligopeptides/pharmacology ; Oligopeptides/therapeutic use ; Viral Load ; Virus Latency/drug effects ; Virus Replication
مستخلص: The "shock and kill" strategy for HIV-1 cure incorporates latency-reversing agents (LRA) in combination with interventions that aid the host immune system in clearing virally reactivated cells. LRAs have not yet been investigated in pediatric clinical or preclinical studies. Here, we evaluated an inhibitor of apoptosis protein (IAP) inhibitor (IAPi), AZD5582, that activates the noncanonical NF-κB (ncNF-κB) signaling pathway to reverse latency. Ten weekly doses of AZD5582 were intravenously administered at 0.1 mg/kg to rhesus macaque (RM) infants orally infected with SIV mac251 at 4 weeks of age and treated with a triple ART regimen for over 1 year. During AZD5582 treatment, on-ART viremia above the limit of detection (LOD, 60 copies/mL) was observed in 5/8 infant RMs starting at 3 days post-dose 4 and peaking at 771 copies/mL. Of the 135 measurements during AZD5582 treatment in these 5 RM infants, only 8 were above the LOD (6%), lower than the 46% we have previously reported in adult RMs. Pharmacokinetic analysis of plasma AZD5582 levels revealed a lower Cmax in treated infants compared to adults (294 ng/mL versus 802 ng/mL). RNA-Sequencing of CD4 + T cells comparing pre- and post-AZD5582 dosing showed many genes that were similarly upregulated in infants and adults, but the expression of key ncNF-κB genes, including NFKB2 and RELB , was significantly higher in adult RMs. Our results suggest that dosing modifications for this latency reversal approach may be necessary to maximize virus reactivation in the pediatric setting for successful "shock and kill" strategies. IMPORTANCE While antiretroviral therapy (ART) has improved HIV-1 disease outcome and reduced transmission, interruption of ART results in rapid viral rebound due to the persistent latent reservoir. Interventions to reduce the viral reservoir are of critical importance, especially for children who must adhere to lifelong ART to prevent disease progression. Here, we used our previously established pediatric nonhuman primate model of oral SIV infection to evaluate AZD5582, identified as a potent latency-reversing agent in adult macaques, in the controlled setting of daily ART. We demonstrated the safety of the IAPi AZD5582 and evaluate the pharmacokinetics and pharmacodynamics of repeated dosing. The response to AZD5582 in macaque infants differed from what we previously showed in adult macaques with weaker latency reversal in infants, likely due to altered pharmacokinetics and less inducibility of infant CD4 + T cells. These data supported the contention that HIV-1 cure strategies for children are best evaluated using pediatric model systems.
References: Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Clin Infect Dis. 2019 Nov 13;69(11):1919-1925. (PMID: 30753360)
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504. (PMID: 11768292)
Nat Med. 2003 Jun;9(6):727-8. (PMID: 12754504)
Science. 1997 Nov 14;278(5341):1295-300. (PMID: 9360927)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
PLoS Pathog. 2012;8(6):e1002774. (PMID: 22737073)
Nat Med. 1999 May;5(5):512-7. (PMID: 10229227)
AIDS Res Hum Retroviruses. 2016 Feb;32(2):163-8. (PMID: 26150024)
Curr Opin HIV AIDS. 2016 Jul;11(4):394-401. (PMID: 26974532)
Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
PLoS One. 2011 Apr 28;6(4):e19006. (PMID: 21552521)
Nat Rev Immunol. 2016 Apr;16(4):259-71. (PMID: 26972723)
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11778-83. (PMID: 18697935)
N Engl J Med. 2016 Feb 25;374(8):761-70. (PMID: 26933850)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
J Virol. 2019 Nov 26;93(24):. (PMID: 31578289)
PLoS Pathog. 2020 Oct 26;16(10):e1008954. (PMID: 33104758)
Immunol Rev. 2012 Mar;246(1):125-40. (PMID: 22435551)
Viruses. 2021 Aug 06;13(8):. (PMID: 34452425)
J Virol. 2018 Aug 29;92(18):. (PMID: 29997216)
Nature. 2014 Aug 7;512(7512):74-7. (PMID: 25042999)
J Virol. 2020 Oct 14;94(21):. (PMID: 32817214)
Pharmaceutics. 2010 Dec 16;2(4):389-418. (PMID: 27721364)
JCI Insight. 2020 Feb 27;5(4):. (PMID: 31999647)
Pharmaceutics. 2011 Feb 07;3(1):53-72. (PMID: 24310425)
Nature. 2020 Feb;578(7793):160-165. (PMID: 31969707)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Sci Transl Med. 2020 Jan 29;12(528):. (PMID: 31996465)
Cell. 2020 Apr 2;181(1):189-206. (PMID: 32220311)
J Virol. 2020 Dec 22;95(2):. (PMID: 33087463)
Pediatr Infect Dis J. 2013 May;32(5):489-94. (PMID: 23249913)
Apoptosis. 2017 Dec;22(12):1487-1509. (PMID: 29067538)
Curr Opin Virol. 2019 Oct;38:1-9. (PMID: 31048093)
Pediatr Infect Dis J. 2011 Nov;30(11):974-9. (PMID: 21734620)
J Immunol. 2010 Jan 1;184(1):303-14. (PMID: 19949089)
Nat Rev Immunol. 2017 Sep;17(9):545-558. (PMID: 28580957)
معلومات مُعتمدة: P30 AI050409 United States AI NIAID NIH HHS; P51 OD011132 United States OD NIH HHS; P30 CA138292 United States CA NCI NIH HHS; UM1 AI164567 United States AI NIAID NIH HHS; S10 OD026799 United States OD NIH HHS; R01 AI133706 United States AI NIAID NIH HHS; U24 OD011023 United States OD NIH HHS; P30 AI050410 United States AI NIAID NIH HHS; U42 OD011023 United States OD NIH HHS; UM1 AI164566 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: HIV; HIV cure; NHP; SIV; pediatric HIV
المشرفين على المادة: 0 (Alkynes)
0 (Anti-Retroviral Agents)
0 (N,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide))
0 (Oligopeptides)
تواريخ الأحداث: Date Created: 20220316 Date Completed: 20220415 Latest Revision: 20230317
رمز التحديث: 20230320
مُعرف محوري في PubMed: PMC9006931
DOI: 10.1128/jvi.01699-21
PMID: 35293766
قاعدة البيانات: MEDLINE
الوصف
تدمد:1098-5514
DOI:10.1128/jvi.01699-21